Vivian T. Laquer
Expertise in
18
conditions

Dr. Vivian T. Laquer

Dermatology
101 The City Drive South, Building 29, 
Orange, CA 
Referral may be required
Expertise in
18
conditions
101 The City Drive South, Building 29, 
Orange, CA 

Overview

Dr. Vivian T. Laquer is a board-certified UCI Health dermatologist who specializes in the diagnosis and management of psoriasis and atopic dermatitis. Her clinical interests include psoriasis, atopic dermatitis, vascular malformations and laser therapy.She earned her medical degree at Columbia University in New York City, followed by an internship in internal medicine at Harbor-UCLA Medical Center. She completed a residency in dermatology at UCI School of Medicine.Laquer, who also speaks Spanish and Vietnamese, sees patients inIrvineandOrange.

Dr. Laquer is highly rated in 18 conditions, according to our data. Her clinical expertise encompasses Atopic Dermatitis, Plaque Psoriasis, Psoriasis, and Actinic Keratosis.

Dr. Laquer is board certified in American Board Of Dermatology - Dermatology. She is actively involved in clinical research, co-authoring 32 peer reviewed articles and participating in 28 clinical trials.

Graduate Institution

Columbia University

Residency

University of California (Irvine) College of Medicine - Dermatology

Specialties

Dermatology

Licenses

Dermatology in CA

Board Certifications

American Board Of Dermatology - Dermatology

Languages Spoken

English
Spanish
Vietnamese

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

UCI Health Dermatology Services
101 The City Drive South, Building 29, Orange, CA 92868
Other Locations
UCI Health - Irvine
19210 Jamboree Road, Irvine, CA 92612

Additional Areas of Focus

Dr. Laquer has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Psoriasis

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

21 Clinical Trials

A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: April 07, 2026
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase 1 Open-label, Multi-centre, Single-arm Trial to Evaluate the Safety and Pharmacokinetics (Including MUsT) of Twice Daily Topical Application of Delgocitinib Cream for 8 Weeks in Adults, Adolescents, and Children With Moderate to Severe Atopic Dermatitis
A Phase 1 Open-label, Multi-centre, Single-arm Trial to Evaluate the Safety and Pharmacokinetics (Including MUsT) of Twice Daily Topical Application of Delgocitinib Cream for 8 Weeks in Adults, Adolescents, and Children With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 24, 2025
Intervention Type: Drug
Study Drug: Delgocitinib Cream
Study Phase: Phase 1
A Phase 2A, Open Label, Proof of Concept Trial of Daxdilimab for the Treatment of Moderate To Severe Alopecia Areata
A Phase 2A, Open Label, Proof of Concept Trial of Daxdilimab for the Treatment of Moderate To Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: January 07, 2025
Intervention Type: Biological
Study Phase: Phase 2
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Psoriasis
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Psoriasis
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug
Study Drug: LY3471851
Study Phase: Phase 1
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Atopic Dermatitis
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug
Study Drug: NKTR-358
Study Phase: Phase 1
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3041658 in Adults With Moderate-to-Severe Hidradenitis Suppurativa
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3041658 in Adults With Moderate-to-Severe Hidradenitis Suppurativa
Enrollment Status: Completed
Publish Date: April 28, 2023
Intervention Type: Drug
Study Drug: LY3041658
Study Phase: Phase 2
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Enrollment Status: Terminated
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
View 9 Less Clinical Trials

32 Total Publications

Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial.
Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial.
Journal: Dermatology and therapy
Published: January 27, 2026
Similar Doctors
Expertise in
16
conditions
Dr. Natasha A. Mesinkovska
Dermatology | Pathology
Expertise in
16
conditions
Dr. Natasha A. Mesinkovska
Dermatology | Pathology
Referral may be required

UCI Health Dermatology Services

101 The City Drive South, Building 29, 
Orange, CA 
 (7.3 miles away)
714-456-7070
Languages Spoken:
English, Macedonian
See accepted insurances
Offers Telehealth

Dr. Natasha A. Mesinkovska is a board-certified UCI Health dermatologist who specializes in the diagnosis and treatment of skin disorders, including skin cancer. Her clinical interests include hair loss, dermatitis and integrative dermatology.She earned her medical degree at the Mayo Clinic in Rochester, Minn., after receiving a doctorate in cancer biology from Wayne State University in Detroit, Mich. She completed an internal medicine internship at the Cleveland Clinic in Ohio, where she also completed a residency in dermatology and a fellowship in dermatopathology.Her research interests include alopecia and dermatitis and she is the author or co-author of many articles in peer-reviewed publications. In addition, she is an investigator on several current clinical trials involving alopecia, atopic dermatitis, psoriasis and skin laxity. She also serves as vice chair for clinical research in the UCI School of Medicine's Department of Dermatology. Dr. Mesinkovska is highly rated in 16 conditions, according to our data. Her clinical expertise encompasses Autosomal Recessive Hypotrichosis, Alopecia Areata, Alopecia Universalis, and Vitiligo.

Expertise in
20
conditions
Expertise in
20
conditions
Referral may be required

Christiane Querfeld, M.D., PH.D.

1500 Duarte Rd, 
Duarte, CA 
 (31.2 miles away)
800-826-4673
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Christiane Querfeld is a Dermatologist practicing medicine in Duarte, California. Dr. Querfeld is highly rated in 20 conditions, according to our data. Her clinical expertise encompasses Mycosis Fungoides, Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, and Sezary Syndrome.

Expertise in
18
conditions
Expertise in
18
conditions
Referral may be required

Office

1450 San Pablo St Ste 2000, 
Los Angeles, CA 
 (33.0 miles away)
323-442-8500
Languages Spoken:
English
See accepted insurances
Offers Telehealth

April Armstrong is a Dermatologist practicing medicine in Los Angeles, California. Dr. Armstrong is highly rated in 18 conditions, according to our data. Her clinical expertise encompasses Psoriasis, Plaque Psoriasis, Atopic Dermatitis, and Acne.

Frequently Asked Questions about Dr. Vivian T. Laquer

How do I make an appointment with Dr. Vivian T. Laquer?

You can book an appointment with Dr. Vivian T. Laquer by calling their office at 949-824-0606. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Vivian T. Laquer a top-rated expert for Atopic Dermatitis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Vivian T. Laquer is classified as an Distinguished expert for Atopic Dermatitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Vivian T. Laquer specialize in?

While Dr. Vivian T. Laquer is a Dermatology, they have specific expertise in Atopic Dermatitis, Plaque Psoriasis, and Psoriasis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Dermatology.

Does Dr. Vivian T. Laquer participate in research or clinical trials?

Yes. Dr. Vivian T. Laquer has published 32 articles and abstracts on conditions like Atopic Dermatitis. You can view a list of Dr. Vivian T. Laquer's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Vivian T. Laquer accept my insurance?

Dr. Vivian T. Laquer accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 949-824-0606 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Laquer's expertise for a condition
ConditionClose
    View All 15 Advanced Conditions
    View All 56 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile